Navigation Links
Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
Date:5/17/2011

n specific indication and contraindications contained in the label and the extent of the Risk Evaluation and Mitigation Strategies program; uncertainties of litigation and intellectual property and patent protection; reliance on sole-source suppliers; limited sales and marketing resources and dependence upon third parties; risks related to the development of innovative products; risks related to the failure to obtain FDA or foreign authority clearances or approval; noncompliance with FDA or foreign regulations; and our dependence on the performance of our collaborative partners. As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's  QNEXA CRL or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety concerns, that the FDA will not require us to conduct any additional  prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.CONTACT:VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian Korb Chief Financial Officer646-378-2923650-934-5200
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... -- Research and Markets ( ... "Craniomaxillofacial Implants Market - Global Industry Analysis, ... 2022" report to their offering. ... the current and future prospects of the global ... the global market due to increasing facial deformities ...
(Date:7/28/2015)...  SeraCare Life Sciences, a leading partner to ... the American Association of Clinical Chemistry (AACC) meeting ... the University of California, San Francisco (UCSF) for ... (T18) and Trisomy 13 (T13) trophoblast cell line ... materials for Non-Invasive Prenatal Testing (NIPT) of chromosomal ...
(Date:7/28/2015)... , July 28, 2015  PD-Rx Pharmaceuticals, ... announced that it has partnered with Dobson Technologies, ... as a Service (IaaS) product. PD-Rx ... practices across the United States.  Using Dobson Technologies, ... recovery and business continuity, ensure regulatory compliance, and ...
Breaking Medicine Technology:Global Craniomaxillofacial Implants (Plate and Screw Fixator Systems, Bone Graft Substitutes, Distraction Systems, and TMJ Replacement Devices) Market Analysis 2014-2022 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 3PD-Rx Partners With Dobson Technologies 2
... Cell Therapy, Inc. ("Pathfinder")(OTCQB: PFND), a biotechnology company focused ... damage, today announced that effective at the start of ... will change from SYMD to PFND.  The new ticker ... and has been approved by the Financial Industry Regulatory ...
... 2011 Cempra Pharmaceuticals today announced abstracts to ... novel fluoroketolide antibiotic, solithromycin (CEM-101), at the ... (ICAAC) , September 17 to 20, 2011, in ... the safety and routes of administration of CEM-101, ...
Cached Medicine Technology:Pathfinder Cell Therapy, Inc. Announces New Stock Ticker Symbol 2Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 3Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 4Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 5
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... United States with 1 in 68 children currently affected with the disorder. For ... child on the road to recovery is extremely daunting. That’s where Talk About ...
(Date:7/28/2015)... FL (PRWEB) , ... July 16, 2015 (PRWEB) ... ... Insurance Agency, in Miami, FL, that specializes in providing Health insurance quotes to ... multiple carriers clients compare auto insurance rates that best suits their specific needs. ...
(Date:7/28/2015)... ... July 28, 2015 , ... Dr. Aziz Ahmad recently gave ... took place from noon to 1 p.m. Tuesday, June 23, at the Gulf Coast ... , Dr. Ahmad is board-certified in colorectal surgery and has more than 35 years ...
(Date:7/28/2015)... ... July 28, 2015 , ... Healthpointe ’s Cosmetic Laser Institute in Anaheim ... smooth state, and reduces the appearance of fine lines and wrinkles. , According to ... to instantly add volume to your cheek area to correct age-related volume loss in ...
(Date:7/28/2015)... ... , ... According to WFTV on July 15th heroin overdose rates ... cases. According to recent statistic Orlando suffers at least one death weekly as a ... heroin, and law enforcement officials are struggling to keep apace with its distribution. Officers ...
Breaking Medicine News(10 mins):Health News:National TACA Autism Conference Offers Hope and Help to Families Affected by Autism 2Health News:Nations Insurance Solutions Announces Auto, Motorcycle, and Commercial Business Insurance Quotes. 2Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 2Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 3
... some experts, newly born neuronal stem cells in the adult ... these stem cells are to be utilized in this way, ... regulated. , A new study, led by Laurence Katz, ... of the North Carolina School of Medicine, suggests a way ...
... FALLS" , A study by Indiana University ... of their elderly study participants and their postural stability ... in line with recent findings by other researchers involving ... designed to probe cognitive function effective at identifying people ...
... of American,Physicians, Inc. (CAP) today announced that the exceptional ... has again,earned an A+ rating from A.M. Best Company, ... consecutive year that MPT has,achieved this rating., "We ... Rating again this year,",said CEO James L. Weidner. "It ...
... to millions of diabetics who are missed , , FRIDAY, ... for diabetes is being called for to help the ... disease, a new report says. , "Approximately 30 percent ... undiagnosed," study author Dr. Christopher Saudek, of Johns Hopkins ...
... & Asthma Network Mothers of Asthmatics Applauds FDA Public ... and Offers Critical Facts Patients Need to Know, ... their healthcare providers do not know that at the ... Today, FDA urged patients,still using chlorofluorocarbon (CFC) albuterol metered-dose ...
... EXTON, Pa., May 30 Isolagen(TM), Inc. (Amex:,ILE) ... notice from the staff,of the American Stock Exchange (AMEX) ... compliance did not demonstrate its ability,to regain compliance with ... (a)(i)-(iii) of the AMEX Company Guide within the,prescribed time ...
Cached Medicine News:Health News:Indiana University research at the American College of Sports Medicine annual conference 2Health News:Indiana University research at the American College of Sports Medicine annual conference 3Health News:Indiana University research at the American College of Sports Medicine annual conference 4Health News:Indiana University research at the American College of Sports Medicine annual conference 5Health News:Indiana University research at the American College of Sports Medicine annual conference 6Health News:Indiana University research at the American College of Sports Medicine annual conference 7Health News:Mutual Protection Trust Earns Third A+ Rating From A.M. Best 2Health News:Panel Calls for Better Diabetes Screening 2Health News:Get the Facts on the Albuterol Inhaler Transition 2Health News:Get the Facts on the Albuterol Inhaler Transition 3Health News:Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex 2Health News:Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: